Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entero Therapeutics ( (ENTO) ) has issued an update.
On June 25, 2025, Entero Therapeutics, Inc. received an extension from Nasdaq until October 8, 2025, to comply with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company had previously been notified on April 11, 2025, of its non-compliance due to a stockholders’ equity of negative $3,876,738, which was below the required $2.5 million. Failure to meet these requirements could result in delisting, although the company has the option to appeal any delisting decision.
More about Entero Therapeutics
Average Trading Volume: 1,625,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.81M
Find detailed analytics on ENTO stock on TipRanks’ Stock Analysis page.